BioAtla (BCAB) to Release Quarterly Earnings on Thursday

BioAtla (NASDAQ:BCAB) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($8.50) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings results on Friday, May 15th. The company reported ($4.22) EPS for the quarter, beating the consensus estimate of ($10.00) by $5.78.

BioAtla Stock Performance

BCAB opened at $3.26 on Tuesday. The stock has a market capitalization of $5.41 million, a PE ratio of -0.08 and a beta of 0.78. BioAtla has a one year low of $3.12 and a one year high of $71.50. The business’s 50 day moving average price is $3.70 and its 200 day moving average price is $6.59.

Analyst Upgrades and Downgrades

A number of research firms have commented on BCAB. Weiss Ratings restated a “sell (e+)” rating on shares of BioAtla in a research report on Wednesday, June 3rd. Wall Street Zen raised BioAtla to a “hold” rating in a research note on Saturday, April 11th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $200.00.

Hedge Funds Weigh In On BioAtla

Institutional investors have recently modified their holdings of the business. Millennium Management LLC raised its stake in shares of BioAtla by 123.4% in the fourth quarter. Millennium Management LLC now owns 762,394 shares of the company’s stock valued at $433,000 after acquiring an additional 421,072 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in BioAtla in the fourth quarter valued at $104,000. Marshall Wace LLP acquired a new position in BioAtla during the 4th quarter worth $508,000. Jane Street Group LLC grew its stake in BioAtla by 55.4% during the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after purchasing an additional 123,597 shares in the last quarter. Finally, Susquehanna International Group LLP increased its holdings in BioAtla by 237.6% during the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares during the period. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.